The kinase MEKK2 (MAP3K2) has recently been implicated in tumor growth and metastasis. Thus, selective inhibition of MEKK2 may be a novel strategy for cancer therapy. To identify inhibitors of MEKK2 kinase activity, we have developed a novel activity assay for MEKK2 based on the discovery that recombinant purified MEKK2 has intrinsic ATPase activity. This MEKK2 ATPase assay was validated for enzyme identity and enzymatic purity by multiple methods including mass spectrometry analysis, testing different sources of MEKK2 and comparing ATPase assay IC 50 data for multiple inhibitors to literature values and to IC 50 data generated using MEKK2 binding and transphosphorylation assays. Taken together, these data indicated that genuine MEKK2 activity was being measured in this assay and no other ATPases contributed to the signal. A miniaturized version of the assay was validated for high-throughput screening, and compound libraries were screened. The screening hits generated comparable potencies in the MEKK2 intrinsic ATPase, binding, and transphosphorylation assays. We identified a novel MEKK2 inhibitor and confirmed that crizotinib and bosutinib are potent in vitro inhibitors of MEKK2 activity with IC 50 values of <100 nM. Thus, this assay has utility for the discovery of small-molecule inhibitors of MEKK2 activity.
Introduction
Mitogen-activated protein kinases (MAPK) are critical cell-signaling components that transduce extracellular stimuli to the nucleus, ultimately leading to changes in gene expression. 1, 2 ERK5 is a MAPK that is activated by a number of growth factors, oxidative stress, and hyperosmolarity. 3 Disruption of the ERK5 gene in mice resulted in embryonic lethality due to defects in cardiac development and angiogenesis. 4 ERK5 protects many cell types from stress-induced apoptosis. 3, 5, 6 MEK5 is the only MAP2K for the ERK5 pathway. 7 MEK5 gene knockout in mice was lethal and resulted in abnormal cardiac development, similar in phenotype to the ERK5 knockout mouse. 7 The only defined MAP3Ks for the ERK5 pathway are MEKK2 (MAP3K2) and MEKK3 (MAP3K3). 8, 9 These kinases phosphorylate MEK5 and activate its activity. Disruption of the MEKK2 gene in mice resulted in normal development and fertility. 10, 11 In contrast, the disruption of MEKK3 resulted in embryonic lethality due to cardiac development defects that mimicked the ERK5 knockout phenotype. 12 Thus, the different phenotypes of these transgenic animals demonstrate that these two MAP3Ks integrate different stimuli. MEKK2 activates both the ERK5 and JNK pathways. 10, 13 MEKK2 has been observed to autophosphorylate in response to stimuli, and this autophosphorylation is required for activation of MEKK2. 14 The role of the ERK5 pathway in cancer has only relatively recently been explored. Expression of ERK5 in a panel of 84 human early-stage breast cancer tissue samples 466430J BXXXX10.1177/1087057112466430Jo urnal of Biomolecular ScreeningAhmad et al. 2012 1 Department of Pharmaceutical Sciences, Biomanufacturing Research was examined, and overexpression of ERK5 was found in 20% of the samples. 15 Overexpression of ERK5 correlated with a decrease in disease-free survival time. In a similar study done with prostate cancer, ERK5 expression was significantly increased in high-grade prostate cancer compared with benign prostatic hyperplasia. 16, 17 Analysis of ERK5 expression in samples taken before and after hormone relapse showed a correlation with ERK5 activation and hormone-insensitive disease. 17 ERK5 overexpression in PC3 cells resulted in more efficient tumor formation in mice. In another study, a dominant negative form of ERK5 restricted the proliferation of myeloma cells and sensitized the cells to apoptosis-inducing drugs. 18 In a recent study, miR-143 was shown to be a tumor suppressor in prostate cancer using a mouse model. 19 One of the mechanisms of miR-143 appears to be suppression of ERK5 protein expression. Activation of the ERK5 pathway, but not the ERK1 pathway, was correlated with lymph node metastasis in oral squamous cell carcinoma. 20 A potent and selective ERK5 inhibitor has been reported that inhibited tumor growth in an in vivo mouse cancer model. 21 MEK5 has also been implicated in tumor development. MEK5 expression was determined in 127 cases of prostate cancer and 20 cases of benign prostatic hypertrophy. 22 The data indicated that elevated expression of MEK5 correlated with bone metastasis and poor prognosis. In one study linking MEKK2 to cancer, 11 prostate cancer tissue samples were compared with uninvolved prostate tissue using imaging mass spectrometry (MS). 16 One peptide was found to discriminate cancer from uninvolved tissue. This peptide was a fragment of MEKK2.
In confirmation of the MS data, MEKK2 was expressed at 4.4-fold higher level in prostate cancer tissue versus benign tissue using Western blotting. Even higher levels of MEKK2 expression were observed in LNCaP, Du145, and PC3 prostate cell lines. We have recently examined the role of MEKK2 in tumor growth and metastasis using an in vivo mouse xenograft model for breast cancer. 23 We found that shRNA-mediated knockdown of MEKK2 inhibited activation of ERK5 in response to epidermal growth factor (EGF) in the breast cancer cell line MDA-MB-231. Knockdown of MEKK2 expression strongly inhibited both tumor growth and metastasis. Increased apoptosis was observed with the loss of MEKK2 expression in xenografts versus size-matched control tumors, even though growth of MEKK2 knockdown cells in culture was unaffected. MEKK2 shRNA knockdown in the BT474 cell line also resulted in inhibited tumor growth in xenografts. Thus, MEKK2 is critical for EGFRand Her2/Neu tyrosine kinase-dependent ERK5 activation, tumor growth of both MDA-MB-231 and BT474 cells, and metastasis of MDA-MB-231 cells. Because MEKK2 is required for EGFR activation of ERK5, we assessed whether knockdown of ERK5 in MDA-MB-231 cells would show similar tumor growth and metastasis phenotypes as with MEKK2 knockdown. ERK5 knockdown resulted in a decrease in metastasis without a significant effect on tumor growth. Thus, MEKK2 regulation of ERK5 is only one arm of MEKK2 signaling controlling tumor growth and metastasis. These results further support MEKK2 as a novel target for small-molecule inhibitor development.
Kinase intrinsic ATPase activity is the hydrolysis of ATP to ADP and phosphate in the absence of a phosphate-accepting substrate. Intrinsic ATPase activity has been observed for a number of kinases using in vitro biochemical assays and purified kinase. This ATPase activity has been described for several MAPKs, including p38α, p38γ, ERK2, JNK3, and MEK1. 24, 25 A format comparison study compared screening results using an antibody-based disassociation-enhanced lanthanide fluoroimmunoassay, an ATP-consumption intrinsic ATPase assay, and a fluorescence polarization binding assay for ITK. 26 The authors concluded that the intrinsic ATPase assay identified the most comprehensive set of inhibitors from screening. In another study using PI3Kα, IC 50 data for a panel of inhibitors generated using an intrinsic ATPase assay were similar to data generated by a lipid phosphorylation assay. 27 We have discovered that MEKK2 has intrinsic ATPase activity and have developed a high-throughput MEKK2 activity assay based on this property. Multiple methods were employed to demonstrate that genuine MEKK2 activity was being measured and no other ATPase activities contributed to the assay signal. In addition, a miniaturized version of the assay was validated for high-throughput screening (HTS), and compound libraries were screened. Using this assay, a novel MEKK2 inhibitor was identified, and crizotinib and bosutinib were confirmed to inhibit MEKK2 activity with IC 50 values of <100 nM.
Materials and Methods Materials
All common reagents such as HEPES, Triton X-100, MgCl 2 , ethylene glycol tetraacetic acid (EGTA), sodium orthovanadate, β-glycerophosphate, dithiothreitol (DTT), and DMSO were reagent grade quality and obtained from Thermo Fisher Scientific (Waltham, MA) or Sigma-Aldrich (St. Louis, MO). The ADP-Glo kinase assay kit (cat no. V9102), containing ADP-Glo, detection reagent, and ultrapure ATP, was obtained from Promega (Madison, WI). Solid white 96-well half-area plates (cat no. 3693) for the manual activity assay and 384-well low-volume white plates (cat no. 3673) for the high-throughput activity assay and binding assay were from Corning Incorporated (Corning, NY). Falcon polypropylene plates (cat no. 1190) used for serial dilutions of compounds for manual activity and binding assays were obtained from Becton Dickinson (Franklin Lake, NJ). Kinase inhibitors were obtained from Fisher Chemical (Waltham, MA), LC Laboratories (Woburn, MA), Selleck Chemicals (Houston, TX), AK Scientific (Union City, CA), Biovision (Milpitas, CA), Toronto Research Chemicals (Toronto Canada), and Symansis (Shanghai, China). The validation set of compounds for test screening was obtained from Prestwick Chemical (Washington, DC). The kinase-focused library of compounds was obtained from The Center for Integrative Chemical Biology and Drug Discovery at the University of North Carolina at Chapel Hill (Chapel Hill, NC). Recombinant purified MEKK2 enzyme was obtained from SignalChem (Richmond, BC, Canada; vendor 1), Invitrogen (Grand Island, NY; vendor 2), and Carna Bioscience (Kobe, Japan; vendor 3). We used the MEKK2 enzyme from SignalChem (vendor 1) to generate the data shown in this report unless otherwise indicated. LanthaScreen Eu-antiglutathione S-transferase (GST) antibody (cat no. PV5594) and Kinase Tracer 236 (cat no. PV5592) used in the binding assays were obtained from Invitrogen. Protease digestion and matrix-assisted laser desorption/ionization-time of flight/time of flight (MALDI-TOF/TOF) analysis of the MEKK2 solution was performed by the Proteomics Core Facility, UNC-Chapel Hill.
MEKK2 Intrinsic ATPase Activity Assay
All compound stock solutions were made in 100% DMSO. Serial dilutions of compounds for IC 50 determinations were initially performed in 100% DMSO in 96-well polypropylene plates, followed by appropriate dilutions in assay buffer (50 mM HEPES, pH 7.4, 10 mM MgCl 2 , 0.5 mM EGTA, 0.5 mM sodium orthovanadate, 0.5 mM β-glycerophosphate, 2.5 mM DTT, and 0.01% Triton X-100), producing a constant 2.5% DMSO in all wells. Subsequently, 10 µL of the diluted compound (or just 2.5% DMSO in assay buffer for controls) was added to the wells of a 96-well plate followed by 10 µL of MEKK2 enzyme diluted in assay buffer. After a 10-min incubation, the reactions were initiated by addition of 5 µL of ATP (150 µM ultrapure ATP from Promega kit) diluted in assay buffer, and the assay plates were centrifuged at 1000 rpm for 1 min in a Beckman Coulter Allegra X-12R centrifuge. Final concentrations in the assembled standard assay were as follows: 1x assay buffer, 1% DMSO, 30 µM ATP, and 10 nM MEKK2 enzyme. The enzyme reactions were allowed to proceed protected from light for 75 min at 23 °C and terminated by the addition of 25 µL of solution 1 (ADP-Glo Reagent, Promega). At this point, assay plates were centrifuged again as described above and incubated at 23 °C for an hour. A 50 µL volume of solution 2 (detection reagent) of the Promega kit was added to each well, and the plates were incubated for 1 h at 23 °C, protected from light. The plates were read using an endpoint luminescence protocol (measurement interval time: 1.0 s, optic module: LUM plus, gain: 3600, focal height: 13.7 mm, positional delay: 0.1 s) in a BMG PHERAstar (BMG Labtech, Cary, NC) plate reader. Luminescence data, expressed in relative luminescence units (RLU), were normalized to DMSO (100% activity) and "no enzyme" (0% activity) controls as maximum and minimum responses, respectively.
For all MEKK2 assay formats, compound concentrationresponse curves were generated using data points that represent the average of three determinations per concentration, except for the transphosphorylation assay, in which duplicate determinations were performed. All IC 50 values provided in this report are averages of at least three independent determinations. The IC 50 values and Hill slopes were calculated from concentration-response data using GraphPad Prism software (GraphPad Software Inc., La Jolla, CA) employing either a four-parameter or a three-parameter (fixed bottom) curve fit.
High-Throughput MEKK2 Activity Assay
The activity assay described above was readily adapted to an automated 384-well assay version in which handling of compound dilutions, delivery of reagents, and mixing was performed on a Biomek NX (Beckman Coulter Inc., Fullerton, CA) and a Nanoscreen NSX 1536 (Charleston, SC). The automated assay was carried out exactly as the manual assay including incubation times and centrifugation with the following modifications. 2.5 µL of enzyme solution was added to 384-well white solid low-volume assay plates. Compounds of 50 nL in 100% DMSO (or 100% DMSO as controls) were added to each well using a V&P Scientific pin tool (San Diego, CA). After 10 min, 2.5 µL of ultrapure ATP was added to each well, bringing the final assay volume to 5 µL. The reaction was terminated by addition of 5 µL of solution 1 (ADP-GLO), and following 60 minutes of incubation, 10 µL of solution 2 (detection reagent) was added. The plates were sealed with Mylar Plate Seals (Thermo, Milford, MA) during incubations. The kinase inhibitor library was screened at 5 µM concentration, and compounds with ≥50% inhibition were considered hits. Z′-factor calculations were performed as published. 28
MEKK2 TR-FRET Binding Assay
Compound dilution methods and assay buffer was the same for the MEKK2 time-resolved fluorescence resonance energy transfer (TR-FRET) binding assay as in the ATPase assay. The assay was performed according to the antibody and tracer manufacturer's recommendations (Invitrogen). Briefly, 5 µL of diluted compounds (or 3% DMSO for controls) were added to wells of a solid white low-volume 384-well plate followed by 5 µL of a mixture of MEKK2 enzyme and LanthaScreen Eu-anti-GST antibody diluted in assay buffer. Immediately after addition of the enzymeantibody mixture, the reaction mixtures were completed by the addition of 5 µL of kinase tracer 236 diluted in assay buffer. The assay plates were then centrifuged at 1000 rpm for 1 min as before and incubated for 60 min at 23 °C. Final concentrations in the assembled assay were as follows: 1% DMSO, 2 nM LanthaScreen Eu-anti-GST antibody, 25 nM kinase tracer, and 5 nM MEKK2 enzyme. Time-resolved fluorescence was measured using a BMG PHERAstar with the following parameters: number of flashes per well: 300, optic module: HTRF, excitation: 337 nm, emission A: 665 nm, emission B: 620 nm, integration start (µs): 100, integration time (µs): 200, focal length: 10.3 mm, ratio multiplier: 1000, positional delay: 0.1. The TR-FRET signal was calculated by determining the ratio of relative fluorescence units obtained at 665 nm and 620 nm (665 nm/620 nm) and subsequently normalizing the value to DMSO (100% activity) and 30 µM dasatinib (0% activity) controls as maximum and minimum responses, respectively.
MEKK2 Transphosphorylation Activity Assay
The MEKK2 transphosphorylation activity assay and IC 50 determinations were performed as described for the ATPase assay, except the reactions were initiated by a mixture of ATP and kinase-inactive mutant MKK6 (MAP2K6, Carna Biosciences). Final concentrations in the enzyme reactions were 2 nM MEKK2, 200 nM MKK6, and 3 µM ATP. The reaction time was 25 min, and the reactions were stopped by the addition of 225 µL of stop buffer (25 mM HEPES, pH 7.4, 10 mM EDTA). These reactions were then transferred to polyvinylidene difluoride membranes using a slot blot apparatus (Hoefer PR 648) following the manufacturer's recommendations. The membrane was allowed to dry and then probed with an anti-phosphoMKK6 antibody (Phospho-MKK3 [Ser189]/MKK6 [Ser207] [22A8] rabbit monoclonal antibody; Cell Signaling, Danvers, MA) using a standard Western blotting protocol. 29 
Results

Characterization of MEKK2 Intrinsic ATPase Activity
We sought to develop a high-throughput activity assay for MEKK2 to identify small-molecule inhibitors of this kinase. Using a sensitive chemiluminescent ADP detection assay (ADP-Glo kit, Promega), we observed ATPase activity using purified recombinant MEKK2 enzyme in the absence of any protein substrate. This ATPase activity increased in a linear fashion directly proportional to the concentration of MEKK2 in the reaction up to 10 nM ( Fig. 1A) . ATPase activity was readily detected even at 1 nM MEKK2. Reaction time course studies with 10 nM MEKK2 demonstrated a linear assay signal increase from 0 to 90 min ( Fig. 1B) . Thus, we chose final reaction conditions of 10 nM MEKK2 and a reaction time of 75 min. The K m for ATP was determined by performing reactions with variable concentrations of ATP with and without MEKK2 (Fig. 1C) . Reactions without MEKK2 were taken as background and subtracted from the signal obtained with enzyme to obtain specific RLU. The average K m value was 34 µM, and thus, we chose to use 30 µM ATP for the final assay. We also used pure ADP to determine a standard curve (data not shown). Under final standard assay conditions, we calculated that approximately 3 µM ADP was generated, translating into a 10% substrate conversion (ATP to ADP). The activity observed in this assay is unlikely to be MEKK2 autophosphorylation activity based on the ratio of the amount of product formed to the MEKK2 enzyme concentration. Because there is only 10 nM MEKK2 and 3000 nM ADP generated during the course of the reaction, each molecule of MEKK2 would have to be autophosphorylated 300 times, roughly twice the sum of all the serine, threonine, and tyrosine residues in the GST-MEKK2 construct. Because this assay would be used to test compounds dissolved in DMSO, the DMSO tolerance of the assay was assessed ( Fig. 1D) . Up to 8% DMSO was tolerated in the assay without significant effect. The final DMSO concentration in the reaction under final assay conditions was set at 1% DMSO.
Validation of the Identity and Enzymatic Purity of MEKK2 in the Intrinsic ATPase Activity Assay
We purchased purified recombinant human MEKK2 and confirmed its identity by mass spectrometry analysis. The entire MEKK2 enzyme (vendor 1) solution was subjected to enzymatic digestion followed by MALDI TOF/TOF MS analysis of the resulting peptides. Peptides matching human MEKK2 were observed, but no other peptides were detected (data not shown).
Nonselective assay formats, such as measuring ADP generation for kinase assays, require an extra amount of enzymatic purity validation to prove that the target activity, and only that activity, is being measured. We used several experimental approaches to validate that the observed ATPase activity was due to MEKK2 and only MEKK2. In one approach, we obtained purified recombinant human MEKK2 from three different vendors because if contamination was the source of activity, then it is less likely (though possible) that the all three sources would have the same contaminating ATPase at the same concentration or activity level. We demonstrated that all three sources of MEKK2 had time-dependent ATPase activity with similar specific activities, because they were all tested at 10 nM MEKK2 ( Fig. 2A) . Furthermore, we used sunitinib as a control inhibitor to determine its potency using all three sources of MEKK2 (Fig. 2B) . The concentration-response data produced average IC 50 values and standard deviations (SDs) of vendors 1, 2, and 3, respectively. The sunitinib potencies were all within twofold of each other, and therefore, these data suggested that the same enzyme activity was being measured in all three sources of MEKK2. When inhibiting a single enzyme in any biochemical assay, a Hill slope of 1.0 is indicative of the measurement of a single enzyme, versus multiple enzymes that could be present and detected in the assay. Broad (<1) slopes may indicate that more than one enzyme is being measured in the assay. Thus, we also analyzed the Hill slope data from these IC 50 curves. The average Hill slope values and SDs from these inhibitor curves were 1.06 ± 0.16, 1.01 ± 0.02, and 1.01 ± 0.05 for vendors 1, 2, and 3, respectively. The slopes for the different MEKK2 sources were very close to 1.0, indicating that a single ATPase enzyme was being measured and inhibited in all three sources of MEKK2. Sunitinib also demonstrated complete inhibition of activity at high compound concentrations ( Fig. 2B) , which is also expected for measurement of a single enzyme activity. It should also be noted that vendor 3 MEKK2 is different from the other two in that the vendor 3 protein construct consists of only the catalytic domain of MEKK2. These data from different sources of MEKK2 indicate that MEKK2 has intrinsic ATPase activity in vitro. Vendor 1 MEKK2 was used for all experimental data and screening shown and cited in this report, except as indicated in Figure 2 .
We further validated that the assay was measuring genuine MEKK2 activity and not a contaminant ATPase or kinase by using a panel of four kinase inhibitors for inhibitor-based enzymatic purity studies. Inhibitor concentrationresponse curves were generated for sunitinib, dasatinib, VX-680, and staurosporine using the intrinsic ATPase activity assay (Fig. 2C) . Sunitinib, dasatinib, and VX-680 generated IC 50 values (nM) and SDs of 337 ± 157, 753 ± 268, and 3603 ± 826, respectively ( Table 1) . These values are comparable (within threefold and the same rank order) to data provided by Invitrogen using their MEKK2 ; Table 1 ). Staurosporine is a very potent inhibitor of MEKK2 and behaved as a tight binding inhibitor in the ATPase assay. Therefore, the MEKK2 concentration in the reaction was reduced to 1 nM to obtain valid IC 50 and Hill slope data for staurosporine. Titration of staurosporine resulted in an average IC 50 and SD of 1.0 ± 0.6 nM ( Table 1) . This IC 50 value also favorably compared with the reported Invitrogen TR-FRET binding assay IC 50 of 4.2 nM for staurosporine. Using a different bead-based competition binding assay for MEKK2, K d values for these same compounds were published as part of a large kinase profiling panel. 30 This published binding data gave the same rank order as we obtained, and our IC 50 values differed from these published K d values by 2.4-fold to 6-fold ( Table 1) . Using our ATPase assay, the average Hill slopes for this panel of inhibitors ranged from 0.93 to 1.1 (see Table 1 ), which was indicative of a single enzyme species being measured. Furthermore, at high concentrations, all compounds were able to completely inhibit the enzyme activity (Fig. 2C) . The compounds in this set were tested for assay interference by adding compound after completion of the MEKK2 enzyme reaction. None of these compounds demonstrated inhibition of the assay format (data not shown). Thus, this panel of structurally diverse and varied potency inhibitors confirmed enzymatic purity of the ATPase activity assay (i.e., a single enzyme species was generating signal). In addition, the comparable IC 50 data between our MEKK2 ATPase activity assay and reported MEKK2 binding assays indicated that genuine MEKK2 activity was being measured. 
TR-FRET binding assay (Lanthascreen
Validation of a Miniaturized Semiautomated High-Throughput MEKK2 Activity Assay
We converted this MEKK2 activity assay into a less expensive semiautomated high-throughput assay by reducing volume size from 25 to 5 µL and using pin tools to deliver compound. We assessed assay variability by setting up whole 384-well plates of maximum and minimum signal wells by including or excluding enzyme, respectively, and using DMSO instead of compound (Suppl. Fig. S1A) . "No enzyme" signal mimics the signal at high concentration of inhibitor in this assay (see Fig. 2C ). The Z′ factors calculated from these duplicate HTS validation experiments were 0.68 and 0.77. We tested the validity of the HTS version of the assay to reproducibly and accurately determine compound potency values by performing IC 50 determina-tions with the control inhibitors sunitinib and dasatinib (Fig. 3) . This HTS version of the MEKK2 ATPase assay generated IC 50 values and SDs of 963 ± 178 nM and 1656 ± 319 nM for sunitinib and dasatinib, respectively. These IC 50 values are within threefold of the values determined in the manual assay (see Table 1 ) and acceptable reproducibility with %CVs of <20%. As a final validation step, the small Prestwick collection of predominately Food and Drug Administration (FDA)-approved drugs was screened using the semiautomated HTS version of the MEKK2 ATPase assay (Suppl. Fig. S1B) . The Z′ factors for this screen ranged from 0.61 to 0.78, with an average of 0.71. No actives (≥50% inhibition) were obtained.
Screening for MEKK2 Inhibitors Using the Intrinsic ATPase Activity Assay
A kinase-focused library consisting of 4727 compounds was screened to identify novel MEKK2 inhibitors (Suppl. Fig. S1C) . The Z′ factors for this screen ranged from 0.53 to 0.86, with an average of 0.72. Only two actives (≥50% inhibition) were obtained. To identify other control inhibitors of MEKK2 kinase activity, we screened a small collection of 13 kinase inhibitors, 11 of which are FDA-approved drugs and two in clinical trials. Sunitinib was employed as an internal control. These compounds were screened at 1 µM concentration in the MEKK2 intrinsic ATPase assay, and three hits (≥50% inhibition) were obtained (Fig. 4A) . The hits were pazopanib, crizotinib, and bosutinib.
IC 50 Determinations of Hit Compounds Using Three Different MEKK2 Assay Formats: Intrinsic ATPase, Binding, and Transphosphorylation Assays
The active compounds from screening were initially confirmed by IC 50 determination using the intrinsic ATPase Journal of Biomolecular Screening 18 (4) activity assay. With regard to the large kinase-focused library screen, only one of the two actives repeated activity in IC 50 confirmation using the intrinsic ATPase assay; this hit compound was referred to as compound 1. Compound 1 generated an IC 50 of 299 ± 71 nM in this assay ( Fig. 4B;  Table 2 ). A close analog of this compound (compound 2) was also tested and found to be inactive (>30 µM IC 50 ) and thus served as a specificity control ( Fig. 4B; Table 2 ). From the screening of 13 known kinase inhibitors, pazopanib, crizotinib, and bosutinib confirmed activity with IC 50 values (±SD) in the ATPase assay of 698 ± 163, 75 ± 35, and 59 ± 34 nM, respectively ( Fig. 4C; Table 2 ).
We employed a TR-FRET MEKK2 binding assay as an orthogonal secondary assay to further validate the intrinsic ATPase activity assay and to confirm ATPase assay screening hits. This binding assay measures the binding of compound to the ATP pocket of MEKK2. The MEKK2 binding assay was optimized as indicated by the reagent manufacturer's instructions (Invitrogen Lanthascreen Eu Kinase Binding Assay) using the same source of MEKK2 enzyme and assay buffer. Concentration-response data for sunitinib were generated using the MEKK2 binding assay ( Table 2) . The average IC 50 value and SD in the binding assay was 143 ± 6 nM with an average Hill slope of 0.89 ± 0.04. Therefore, the IC 50 values for sunitinib in the ATPase and binding assay differed by only 2.4-fold, and our binding data were very close to the manufacturer's published IC 50 value (120 nM; Table 1 ). Compound 1 was tested in the MEKK2 binding assay, resulting in an average IC 50 value of 355 ± 134 nM, in close agreement with the 299 nM IC 50 obtained in the ATPase assay ( Table 2 ). The inactive control compound 2 was also inactive (>30 µM IC 50 ) in the binding assay. Thus, compound 1 represents a novel inhibitor of MEKK2. Pazopanib, crizotinib, and bosutinib were also tested in the MEKK2 binding assay, resulting in IC 50 values (±SD) of 1145 ± 211, 24 ± 7, and 64 ± 17 nM, respectively ( Table 2) .
The Hill slopes for these compounds in both binding and ATPase assays were close to expected for single-site binding, ranging from 0.93 to 1.3 (see Table 2 ). None of the compounds in Figure 4 , Table 1 , or Table 2 demonstrated any significant assay interference in either the ATPase or binding assay format (data not shown). Thus, the MEKK2 binding assay data confirmed the MEKK2 inhibitory activity of these compounds discovered with the MEKK2 intrinsic ATPase assay. Furthermore, this panel of five diverse inhibitors ( Table 2 ) demonstrated ≤threefold difference in IC 50 values when comparing the ATPase and binding assay data.
To further validate the screening hits and the ATPase assay, we developed a transphosphorylation assay in which kinase-inactive mutant MKK6 was used as a substrate in MEKK2 enzyme reactions. Stopped reaction mixtures were transferred to membranes using a slot blot protocol, and phosphorylation of MKK6 was measured by a phospho-MKK6-specific antibody. The average apparent K m for ATP in this assay format was determined to be 3.3 µM (data not shown), which is 10-fold lower than in the ATPase assay. Therefore, we used 3 µM ATP in the transphosphorylation assay. Average IC 50 values generated using this transphosphorylation assay for sunitinib, compound 1, crizotinib, and bosutinib were 158, 261, 37, and 29 nM ( Table 2) . These values differ by ≤2.2-fold compared with the ATPase and binding assay potency values. Using a bead-based MEKK2 binding assay as part of a large kinase profiling panel, it has been reported that pazopanib, crizotinib, and bosutinib have K d values of 290, 72, and 30 nM, respectively. 30 Thus, our ATPase data, as well as that from two other formats, are in close agreement with this published binding data. Furthermore, our data confirm that these compounds actually inhibit MEKK2 kinase activity. This multiple-format comparison data further enhanced the validation of the intrinsic ATPase assay as a useful assay for the discovery of MEKK2 inhibitors. 
Discussion
We sought to develop a high-throughput activity assay for MEKK2. Unlike many kinases, MEKK2 and many other members of the MAPK family do not effectively use small synthetic peptides as substrates. Thus, large protein substrates are typically used to measure MEKK2 activity. However, for HTS, this would require large amounts of protein substrate. In developing a biochemical activity assay for MEKK2, we discovered that purified MEKK2 had intrinsic ATPase activity. This ATPase activity was discovered using a universal chemiluminescent ADP detection kit. Although convenient, this type of detection assay requires careful validation to ensure that the observed activity derives from the target kinase (enzyme identity) and no other kinases or ATPases (enzymatic purity). Trace amounts of contaminating ATPases or other kinases in the MEKK2 preparation could also cause the observed ATPase activity.
Multiple independent methods and data were used to verify that the observed ATPase activity derived from MEKK2. First, the identity of the commercially obtained enzyme solution was confirmed to be human MEKK2 by MS, and no other proteins were identified in the solution. Second, we compared three different sources of recombinant baculovirus-expressed and purified MEKK2. All three demonstrated ATPase activity in the absence of added substrate, and even the specific activity was similar among the MEKK2 sources. Unlike the other two vendors' constructs, which were full-length proteins, one of the vendor's MEKK2 consisted of only the kinase domain of MEKK2 yet still maintained ATPase activity. Furthermore, the IC 50 value determination for the control kinase inhibitor sunitinib using all three sources of MEKK2 resulted in IC 50 values within twofold of each other, suggestive of measuring the same activity. Third, inhibitor-based studies were performed using a panel of four inhibitors that had been tested in the MEKK2 binding assay reported by Invitrogen. IC 50 values measured using the ATPase assay were comparable (within two-to fourfold) to Invitrogen's MEKK2 binding assay data. In addition, our data were also consistent with published potencies using a bead-based competition binding assay used for kinome profiling. 30 Dasatinib was reported to have a binding K d value that is 5.4-fold lower than the IC 50 we observed in the ATPase assay ( binding assay data. Thus, there was a striking correlation between inhibition of the ATPase assay and the MEKK2 binding assay, even though these assays measured two different parameters: enzyme activity and ATP pocket binding. In addition, a transphosphorylation assay was developed for MEKK2 using MKK6 as a substrate. The IC 50 values for four of these inhibitors were tested in this activity format as well, and all of the values were within twofold of the ATPase assay values. Taken together, these data indicate that the ATPase activity measured in our assay are derived from MEKK2.
In this type of nonselective kinase assay format, it is always possible that multiple enzymes contribute to assay signal, such as the intended target and trace impurities with high specific activity. The inhibition of two or more enzymes by an inhibitor generally results in a blended IC 50 curve, because of different binding affinities, resulting in a shallow slope (<1). The Hill slopes across all eight diverse inhibitors tested in this study were close to the ideal (1.0) for a single enzyme species, ranging from 0.93 to 1.3. A panel of inhibitors such as this provides strong evidence for enzymatic purity because even similar kinases would be expected to have slightly different affinities for some of the inhibitors. It is also possible that potential contaminating ATPase activity is not inhibited by the inhibitors yet contributes to assay signal. However, this is not the case because all compounds demonstrated complete inhibition of activity at high compound concentrations, consistent with only one homogenous enzyme activity detected.
A screen of a kinase-focused set of compounds with the MEKK2 ATPase assay resulted in one confirmed hit (IC 50 = 299 nM), representing a hit rate of 0.02%. Further screening of a set of known FDA-approved and clinical trial kinase inhibitors generated a hit rate of 23% (3 hits out of 13 compounds). The dramatically different hit rates in these screens is likely due to the types of compounds in the respective libraries: one being unoptimized theoretical inhibitors and the other consisting of potent optimized kinase inhibitor scaffolds. Bosutinib and crizotinib were identified as potent (<100 nM IC 50 ) in vitro inhibitors of MEKK2 kinase activity, confirming and extending a published report on the binding activity of these compounds for MEKK2. In addition, a novel inhibitor (compound 1) was identified through screening using the ATPase assay and its activity confirmed in the MEKK2 binding and transphosphorylation formats.
The described MEKK2 ATPase assay has several advantages as an HTS assay. This assay does not require large amounts of expensive and difficult-to-produce protein substrate, and it can be miniaturized. Unlike the binding assay, this assay has the potential to identify non-ATP competitive inhibitors. It should be noted that the K m for ATP differed by 10-fold between the ATPase and the transphosphorylation assay (30 vs. 3 µM), highlighting the importance of experimentally determining K m for ATP when developing an ATPase kinase assay. This magnitude of shift in ATP K m for Journal of Biomolecular Screening 18 (4) kinase intrinsic ATPase activity has been previously observed. 25 We have developed and optimized a high-throughput activity assay for MEKK2 based on the discovery that MEKK2 has intrinsic ATPase activity. This activity assay for MEKK2 was validated for enzyme identity and enzymatic purity by multiple methods to demonstrate that genuine MEKK2 activity was being measured and no other contaminating activities contribute to the signal. Furthermore, a miniaturized version of the assay was validated for HTS and compound libraries screened. MEKK2 inhibitors were identified that may be useful as research tools or lead to potent and selective MEKK2 inhibitors.
